Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection

Keyphrases

• Antibacterial Treatment 9%
• Antibiotics 18%
• Bezlotoxumab 100%
• CDI Recurrence 9%
• CDI Treatment 9%
• Clinical Cure 18%
• Clinical Recurrence 9%
• Clostridium Difficile Infection 100%
• Confidence Interval 27%
• Cure Rate 9%
• Fidaxomicin 100%
• Infection Rate 18%
• Infection Reduction 9%
• Metronidazole 100%
• Placebo 36%
• Placebo Groups 9%
• Rate Difference 27%
• Recurrence Risk 9%
• Subset-based 9%
• Vancomycin 100%

Immunology and Microbiology

• Bezlotoxumab 100%
• Infection Rate 22%
• Peptoclostridium difficile 100%